Parker v. Mentor Corporation

Filing 224

ORDER deferring ruling on the FDA evidence contained in (154) Motion for Summary Judgment in case 4:08-md-02004-CDL 143 Motion for Summary Judgment in case 3:07-cv-00088-CDL; (116) Motion for Summary Judgment in case 3:07-cv-00101-CDL; (114) Motion for Summary Judgment in case 3:07-cv-00102-CDL; (107) Motion for Summary Judgment in case 3:07-cv-00130-CDL]. Ordered by Judge Clay D. Land on 4/23/2010. Associated Cases: 4:08-md-02004-CDL, 3:07-cv-00088-CDL, 3:07-cv-00101-CDL, 3:07-cv-00102-CDL, 3:07-cv-00130-CDL(esl) Modified on 4/23/2010 (esl).

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF GEORGIA COLUMBUS DIVISION IN RE MENTOR CORP. OBTAPE TRANSOBTURATOR SLING PRODUCTS LIABILITY LITIGATION * MDL Docket No. 2004 4:08-MD-2004 (CDL) * Case Nos. * 3:07-cv-00088 (Parker et al.) 3:07-cv-00101 (Stafford et al.) * 3:07-cv-00102 (Booth et al.) 3:07-cv-00130 (Dover et al.) * ORDER The Court previously denied Mentor Worldwide LLC's ("Mentor") motions for summary judgment, finding that genuine issues of material fact exist as to the design defect, manufacturing defect, and failure to warn claims asserted by all Phase I Georgia Plaintiffs in this Multi-District Litigation proceeding. 223).) (Order, April 22, 2010 (Doc.

Mentor also moved for summary judgment as to any claims

asserted by Plaintiffs based upon a fraud-on-the-U.S. Food and Drug Administration ("FDA") theory. Plaintiffs responded that they were

not asserting any "fraud-on-the-FDA" claims, and the Court previously ruled that any such claims had been abandoned. Nevertheless, it is apparent that the issue of whether evidence related to the FDA regulatory process shall be admissible in this action will recur. Therefore, the Court finds it appropriate to Specifically,

address in limine the admissibility of such evidence.

the issue remains as to whether the following evidence is admissible: (1) evidence that ObTape, the product at issue here, was

"adulterated" and "misbranded" in violation of the Federal Food and Drug Cosmetic Act ("FDCA") and FDA regulations; (2) evidence that Mentor engaged in a pattern of misrepresentation to the FDA before and after launching ObTape; and (3) evidence that Mentor falsely represented to the FDA that ObTape was substantially equivalent to another suburethral sling, Gynecare TVT. DISCUSSION I. Exclusion of FDA Evidence Plaintiffs acknowledge that claims based solely on a company's alleged fraudulent representations to the FDA are preempted by federal law. 344 (2001). Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341, Therefore, evidence supporting any such claim would not

be admissible unless it is relevant to Plaintiffs' remaining products liability regulatory claims. compliance In some circumstances, probative of courts state have law found product

evidence

liability claims.

See, e.g., In re Medtronic, Inc., Implantable

Defibrillators Litig., 465 F. Supp. 2d 886, 900 (D. Minn. 2006) (concluding that "plaintiffs may use evidence-if they are able to produce it-of [manufacturer's] efforts to manipulate the regulatory process in order to prove their negligence and strict liability claims, but they may not bring an independent claim for relief based on fraud-on-the-FDA"); In re St. Jude Med., Inc. Silzone Heart Valves Prods. Liab. Litig., No. MDL 01-1396 JRTFLN, 2004 WL 45503, at *13

2

(D. Minn. Jan. 5, 2004) (finding that plaintiffs' claims were not fraud-on-the-FDA claims in disguise but were valid claims related to medical device manufacturer's inadequate warnings and labeling and concluding that genuine issues of material fact existed in part because of evidence that FDA was not aware of device's risks).1 The

Court must therefore determine whether such evidence is probative of Plaintiffs' state law claims. Plaintiffs seek to introduce the following evidence in support of their state law claims: (1) ObTape was "adulterated" and

"misbranded" in violation of the FDCA and FDA regulations; (2) Mentor engaged in a pattern of misrepresentation to the FDA before and after launching ObTape; and (3) Mentor falsely represented to the FDA that ObTape was substantially equivalent to another suburethral sling,

See, e.g., In re Fossamax Prods. Liab. Litig., 645 F. Supp. 2d 164, 191 n.16 (S.D.N.Y. 2009) ("The cases in this MDL are not governed by federal regulations but by state law theories of negligence and strict liability. Expert testimony on regulatory compliance will assist the jury in determining whether Merck acted as a reasonably prudent pharmaceutical manufacturer. The Court will instruct the jury that it must take the law from the Court and not from any witness."); In re Guidant Corp. Implantable Defibrillators Prods. Liab. Litig., MDL No. 05-1708 (DWF/AJB), Civil No. 06-25 (DWF/AJB), 2007 WL 1725289, at *6-*9 (D. Minn. June 12, 2007) (concluding that plaintiff's negligence and fraud claims were not merely fraud-on-the-FDA claims in disguise because they were based not on any duty to the FDA but on duties to plaintiff); Dawson ex rel. Thompson v. Ciba-Geigy Corp., USA, 145 F. Supp. 2d 565, 573 (D.N.J. 2001) (concluding that plaintiffs' claims were that manufacturer deceived the public, including the plaintiffs; unlike the claims in Buckman, a finding of a violation of FDA rules and regulations was not a necessary element of the plaintiffs' claims). But see Swank v. Zimmer, Inc., No. 03-CV-60-B, 2004 WL 5254312, at *2 (D. Wyo. Apr. 20, 2004) ("[E]vidence of communications with the FDA, used to show that Defendants made misrepresentations, must be excluded.").

1

3

Gynecare TVT.

Mentor contends that this evidence is not relevant to

any of Plaintiffs' state law claims for design defect, manufacturing defect, or failure to warn. evidence. The Court is skeptical as to the relevance of this evidence to Plaintiffs' claims. However, it will defer a final ruling on the Accordingly, Mentor seeks to exclude the

admissibility of such evidence until it hears further from counsel at the pretrial hearing. this evidence would The Court cannot presently conceive of how be relevant to Plaintiffs' design and

manufacturing defect claims.

It is conceivable that Plaintiffs may

be able to tie some of this evidence to their failure to warn claims, depending upon the nature of Mentor's defenses to those claims. At

this time, the Court does not have sufficient information to rule in limine on this evidence and requires the parties to be prepared to address this issue at the pretrial hearing. II. Mentor's Motion to Exclude Certain Witnesses In a related Daubert motion, Mentor seeks to exclude testimony from proposed experts Dr. Linda Brubaker, Dr. Francois Haab, Dr. Anne Meddahi-Pelle, qualified and Dr. Donald expert Ostergard opinion because on FDA they are not

to express an

regulations and

procedures. Proposed

(Mentor's Mot. to Exclude Certain Testimony from Pls.' Witnesses 44.) In their response, Plaintiffs

Expert

represented that they would not tender Dr. Brubaker, Dr. Haab, Dr.

4

Meddahi-Pelle, or Dr. Ostergard regarding FDA regulatory matters. (Pls.' Resp. to Mentor's Mot. to Exclude 49 n.41.) Therefore,

Mentor's Daubert motion is granted as to these four witnesses. Mentor did not argue in either its opening Daubert brief or its reply Daubert brief that the remaining proposed experts--Dr. John Davis; Dr. Paul Ducheyne; Dr. Arnold Lentnek; Dr. Kenneth Mitchell; Dr. George Samaras; Dr. Andrew Siegel; and Dr. Mark Slack--are

unqualified to render an opinion on the FDA's regulatory process or Mentor's compliance with that process. Rather, Mentor argues that

such testimony by them should be excluded because it is not relevant to Plaintiffs' claims. its relevancy As previously explained, the Court will make after hearing from counsel at the

determination

pretrial hearing.

The Court does find these experts qualified to

provide testimony in the area of FDA regulatory compliance, and they will be permitted to do so if the Court rules that such testimony is otherwise relevant. CONCLUSION As explained, Plaintiffs are not asserting a "fraud-on-the-FDA" claim in this action. The Court defers ruling on whether evidence

related to the FDA regulatory process is relevant to Plaintiffs' claims for design defect, manufacturing defect, and failure to warn. The parties shall be prepared to address the relevance issue at the pretrial hearing.

5

IT IS SO ORDERED, this 23rd day of April, 2010.

S/Clay D. Land CLAY D. LAND UNITED STATES DISTRICT JUDGE

6